Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions

Tai Hato; Lipika Goyal; Tim F. Greten; Dan G. Duda; Andrew X. Zhu

doi:10.1002/hep.27246

Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions

Tai Hato, Lipika Goyal, Tim F. Greten, Dan G. Duda, Andrew X. Zhu

Research output: Contribution to journal › Review article › peer-review

223 Scopus citations

Abstract

Immune checkpoint blockade has recently emerged as a promising therapeutic approach for various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical studies have shown the potential benefit of modulating the immunogenicity of HCC. In addition, recent advances in tumor immunology have broadened our understanding of the complex mechanism of immune evasion. In this review we summarize the current knowledge on HCC immunology and discuss the potential of immune checkpoint blockade as a novel HCC therapy from the basic, translational, and clinical perspectives.

Original language	English (US)
Pages (from-to)	1776-1782
Number of pages	7
Journal	Hepatology
Volume	60
Issue number	5
DOIs	https://doi.org/10.1002/hep.27246
State	Published - Nov 1 2014

ASJC Scopus subject areas

Hepatology

Access to Document

10.1002/hep.27246

Cite this

@article{cf2a452f686c4718a52fb9a0c147eb21,

title = "Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions",

abstract = "Immune checkpoint blockade has recently emerged as a promising therapeutic approach for various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical studies have shown the potential benefit of modulating the immunogenicity of HCC. In addition, recent advances in tumor immunology have broadened our understanding of the complex mechanism of immune evasion. In this review we summarize the current knowledge on HCC immunology and discuss the potential of immune checkpoint blockade as a novel HCC therapy from the basic, translational, and clinical perspectives.",

author = "Tai Hato and Lipika Goyal and Greten, \{Tim F.\} and Duda, \{Dan G.\} and Zhu, \{Andrew X.\}",

note = "Publisher Copyright: {\textcopyright} 2014 by the American Association for the Study of Liver Diseases.",

year = "2014",

month = nov,

day = "1",

doi = "10.1002/hep.27246",

language = "English (US)",

volume = "60",

pages = "1776--1782",

journal = "Hepatology",

issn = "0270-9139",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Immune checkpoint blockade in hepatocellular carcinoma

T2 - Current progress and future directions

AU - Hato, Tai

AU - Goyal, Lipika

AU - Greten, Tim F.

AU - Duda, Dan G.

AU - Zhu, Andrew X.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Immune checkpoint blockade has recently emerged as a promising therapeutic approach for various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical studies have shown the potential benefit of modulating the immunogenicity of HCC. In addition, recent advances in tumor immunology have broadened our understanding of the complex mechanism of immune evasion. In this review we summarize the current knowledge on HCC immunology and discuss the potential of immune checkpoint blockade as a novel HCC therapy from the basic, translational, and clinical perspectives.

AB - Immune checkpoint blockade has recently emerged as a promising therapeutic approach for various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical studies have shown the potential benefit of modulating the immunogenicity of HCC. In addition, recent advances in tumor immunology have broadened our understanding of the complex mechanism of immune evasion. In this review we summarize the current knowledge on HCC immunology and discuss the potential of immune checkpoint blockade as a novel HCC therapy from the basic, translational, and clinical perspectives.

UR - https://www.scopus.com/pages/publications/84922214829

UR - https://www.scopus.com/inward/citedby.url?scp=84922214829&partnerID=8YFLogxK

U2 - 10.1002/hep.27246

DO - 10.1002/hep.27246

M3 - Review article

C2 - 24912948

AN - SCOPUS:84922214829

SN - 0270-9139

VL - 60

SP - 1776

EP - 1782

JO - Hepatology

JF - Hepatology

IS - 5

ER -

Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this